Loading…
The partnership aims to advance AI-driven drug discovery.
Absci Corporation and AMD announced a collaboration and strategic investment on January 8, 2025. The partnership involves a $20 million investment from AMD to Absci, aimed at accelerating advancements in AI-driven drug discovery.
The investment will support joint efforts in developing AI technologies to enhance the drug discovery process. Absci's free float stands at 132,725,000 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.